Monthly Prescribing Reference

Xolair for the Treatment of IgE-Mediated Food Allergies

In February 2024, the US Food and Drug Administration (FDA) approved Xolair (omalizumab; Genentech, Inc), an anti-immunoglobulin E (IgE) antibody, for the treatment of IgE-mediated food allergies in ...
Monthly Prescribing Reference

Xolair Approved for Adults and Pediatric Patients With IgE-Mediated Food Allergy

Findings showed that compared with placebo, Xolair significantly increased the amount of peanut, milk, egg, and cashew participants could consume without an allergic reaction. The Food and Drug ...
FOX 5 Atlanta

FDA authorizes new treatment for accidental food allergy exposures

ATLANTA - If you have to be vigilant about what you eat, and keep an EpiPen close, Dr. Tom Chacko of Chacko Allergy, Asthma and Sinus Center, says the newly FDA-authorized allergy medication, Xolair, ...
Nasdaq

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

– Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could ...
WISN 12 NEWS

FDA approves medication used to treat asthma for use in people with multiple food allergies

There's been *** rise in childhood food allergies in recent years affecting Children nationwide. These 12 Long Island investigative reporter Rachel Yank Kunis is here now to break down the numbers for ...
CNN

New data shows asthma medicine may help reduce severe reactions in people with multiple food allergies

A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...
The Trentonian

Novartis receives FDA approval of Xolair(R) (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...
Business Wire

FDA Accepts Supplemental Biologics License Application for Xolair (omalizumab) for the Treatment of Nasal Polyps

– The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal ...
Seeking Alpha

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

– Results were featured as late-breakers at the 2025 AAAAI Annual Meeting – – Xolair is the only U.S. FDA-approved medicine to reduce allergic reactions in children and adults with one or more food ...
Business Wire

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Nasdaq

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Basel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, ...